Check Before You Invest : Venmax Drugs And Pharmaceuticals Ltd

Snapshot

Q.1 Which industry/sub-sector does Venmax Drugs And Pharmaceuticals Ltd belong to?

Venmax Drugs And Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Venmax Drugs And Pharmaceuticals Ltd a good quality company?

Venmax Drugs And Pharmaceuticals Ltd is a quality company, based on a 6-year financial track record.

Q.3 Is Venmax Drugs And Pharmaceuticals Ltd undervalued or overvalued?

Venmax Drugs And Pharmaceuticals Ltd appears Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Venmax Drugs And Pharmaceuticals Ltd a good buy now?

Venmax Drugs And Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd revenue growth is 0% for FY-2025, which is below its 5-year CAGR of 11.5%, indicating slower growth.

Q.2 Return on Asset of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Return on Asset is -0.4%, which is below its 5-year historical median of 44.06%, indicating deteriorated asset utilization efficiency.

Q.3 Gross Profit margin of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is -1% for FY-2025, which is above its 5-year median of -90.2%, indicating increasing margins.

Q.4 Operating Profit Margin of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -131.31% for FY-2025, which is above its 5-year median of -157.76% indicating increasing margins.

Q.5 Net Profit Margin of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Net Profit Margin is -1.3% for FY-2025, is above with its 5-year median of -96.78%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-1	-90.2
Operating Profit Margin	-131.31	-157.76
Net Profit Margin	-1.3	-96.78

Q.6 Debt to Equity ratio of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Debt-to-Equity ratio is -0.08, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.7 Debt to cash flow from operations of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd Debt to cash flow from operations is -0.02, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Venmax Drugs And Pharmaceuticals Ltd?

Promoters hold 13.80% of the Venmax Drugs And Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Venmax Drugs And Pharmaceuticals Ltd vs industry peers?

Venmax Drugs And Pharmaceuticals Ltd revenue CAGR is 11.50%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-	8.3
Gross Profit Growth	-111.1	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	-116.7	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.31	0.81
ROE	-	9.49
ROCE	-	11.91
Cash Conversion Cycle (days)	80.83	85

Valuation & price assessment

Q.1 Stock return of Venmax Drugs And Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 23.6% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	23.6%	42.4%	80.3%	-7.6%

Q.3 Valuation ratios of Venmax Drugs And Pharmaceuticals Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	32.63	9.69	31.09
Price to Book	1.71	-1.13	2.85
Price to Sales	6.43	7.93	2.79
EV to EBITDA	33.46	10.85	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Force Motors Ltd.

2. KEI Industries Ltd.

3. Aadhar Housing Finance Ltd.

4. State Bank Of India

5. Power Finance Corporation Ltd.